Research and Markets - Global $248.7 Billion Protein Drugs Markets and Manufacturing Technologies, 2020: Major Players Include Eli Lilly & Co, Abbvie F. Hoffmann-La Roche, Sanofi, Novo Nordisk, Novartis, Merck & Co. & Amgen
DUBLIN, October 10, 2016 /PRNewswire/ --
Dublin - Research and Markets has announced the addition of the "Global Markets and Manufacturing Technologies for Protein Drugs" report to their offering.
The global protein drugs market reached nearly $174.7 billion in 2015 and should reach nearly $248.7 billion by 2020 at a compound annual growth rate (CAGR) of 7.3% through 2020.
The scope of this study covers manufacturing of protein drugs technologies. Each market and its applications, regulatory environment, technology, market projections and market shares were analyzed. Technological issues include the latest trends and developments. This report covers the currently used six techniques in manufacturing of protein therapeutics, which includes fractionation from natural human/animal sources, microbial fermentation, cell culture, chemical synthesis, transgenics and embryonated eggs.
The emerging market for enzyme inhibitors includes countries such as India, China, Japan, Korea, Taiwan, Canada, Africa, Australia and New Zealand. The protein drugs that are covered in this report are monoclonal antibodies, cytokines, peptide antibiotics, vaccines, enzymes and blood factors. The market is also analyzed on the basis of the manufacturing process used in making therapeutic protein drugs.
Also included in the report are relevant patent analysis and comprehensive profiles of companies that lead the manufacturing of the protein drug industry.
Some of the major players of the market include
- Eli Lilly & Co.
- Abbvie Inc.
- F. Hoffmann-La Roche Ltd
- Sanofi S.A
- Novo Nordisk AG
- Novartis AG
- Merck & Co.
- Merck KGaA
- Amgen Inc.
This report will provide:
- An overview of the markets for each major class of protein in the segments therapeutic monoclonal antibodies, cytokines, peptide hormones, vaccines, and blood products
- Analyses of global market trends, with data from 2014, estimates for 2015, and projections of compound annual growth rates (CAGRs) through 2020
- Discussion covering the strength and weaknesses of each type of technology in light of the new technologies, growing competition, and changing customer needs
- Examinations of current successes, including the size and sales forecast for each class in the next five years
- Evaluation of challenges such as delivery methods and side effects
- Consideration of issues regarding add-on products and patent protection
- Company profiles of major players
Key Topics Covered:
Chapter 1: Introduction
Chapter 2: Executive Summary
Chapter 3: Overview
- History
- Pharmacological Classification Of Therapeutic Proteins
- Molecular Classification Of Therapeutic Proteins
- Manufacturing Technologies
Chapter 4: Regulatory Aspects
- Monoclonal Antibodies
- Therapeutic Enzymes
- Cytokines
- Peptide Hormones
- Vaccines
- Blood Products
- Peptide Antibiotics
- Recalls
- Safety Alerts
Chapter 5: New Developments
- Monoclonal Antibodies
- Vaccines
- Cytokines
- Peptide Hormones
- Peptide Antibiotics
- Therapeutic Enzymes
- Blood Products
- Mergers And Acquisitions
Chapter 6: Market Analysis By Type
Chapter 7: Market Analysis By Manufacturing Process
Chapter 8: Industry Structure
- Peptide Hormones
- Vaccines
- Therapeutic Enzymes
- Monoclonal Antibodies
- Cytokines
- Blood Factors
- Peptide Antibiotics
Chapter 9: Patent Analysis
- Patents By Year
- Patents By Type
- Patents By Company
- Patents By Country
- Patents By Assignee
Chapter 10: Current Situation
- Factors Affecting The Protein Therapeutic Market
Chapter 11: Company Profiles
- Abbvie Inc.
- Actavis Inc.
- Alexion Pharmaceuticals
- Allergan PLC
- Amgen Inc
- Apotex Inc.
- Baxalta Inc
- Bayer Pharma AG
- Biogen Inc.
- Biomarin Pharmaceutical Inc
- Biotest Pharmaceuticals Corp.
- Bristol-Myers Squibb
- CSL Limited
- ELI Lilly
- F. Hoffmann-La Roche AG
- Fresenius Kabi USA
- Glaxosmithkline
- Grifols USA LLC
- Hospira Inc
- Johnson & Johnson
- Medimmune Llc
- Merck & Co, Inc
- Merck KGAA
- Mylan Inc.
- Novartis AG
- Novo Nordisk AG
- Octapharma AG
- Pfizer Inc
- Protein Sciences Corp.
- Revo Biologics Inc.
- Sandoz
- Sanofi Inc
- Seattle Genetics Inc.
- Spectrum Pharmaceuticals Inc
- Takeda Pharmaceutical U.S.A., Inc
- UCB Company
- Shire PLC (Viropharm Inc.)
- Vertex Pharmaceuticals
For more information about this report visit http://www.researchandmarkets.com/research/4hf2x2/global_markets
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Share this article